Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 7,163 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 7,163 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $36.49, for a total transaction of $261,377.87. Following the transaction, the chief financial officer owned 284,321 shares of the company’s stock, valued at $10,374,873.29. This trade represents a 2.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total transaction of $619,243.91.
• On Monday, May 18th, Oluyemi Okupe sold 7,950 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.64, for a total value of $187,938.00.
• On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.96, for a total value of $588,564.20.
• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.90, for a total value of $956,279.80.
• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.83, for a total value of $501,079.15.

Hims & Hers Health Trading Down 5.5%

Shares of Hims & Hers Health stock traded down $2.10 on Tuesday, reaching $36.19. The company had a trading volume of 11,881,154 shares, compared to its average volume of 29,273,385. The firm has a market cap of $8.38 billion, a price-to-earnings ratio of -402.06, a P/E/G ratio of 52.60 and a beta of 2.35. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The firm’s 50-day moving average price is $28.81 and its two-hundred day moving average price is $26.32. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.20 EPS. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc increased its position in shares of Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after acquiring an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB grew its stake in Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after purchasing an additional 319 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Hims & Hers Health during the 4th quarter worth $28,000. Binnacle Investments Inc bought a new stake in Hims & Hers Health during the 3rd quarter valued at $28,000. Finally, Bogart Wealth LLC raised its position in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 632 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on HIMS shares. JPMorgan Chase & Co. dropped their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research report on Friday, May 22nd. Truist Financial boosted their target price on Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a research report on Friday, May 22nd. Needham & Company LLC upped their target price on Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, Leerink Partners increased their price target on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a report on Monday, March 16th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $30.63.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.